136 related articles for article (PubMed ID: 33856410)
21. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T; Cai J; Botwood NA; Labriola DF
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558277
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
23. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
25. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
[TBL] [Abstract][Full Text] [Related]
26. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
27. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
28. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
29. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
36. Accounting for Cured Patients in Cost-Effectiveness Analysis.
Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
38. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
39. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
40. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Bullement A; Latimer NR; Bell Gorrod H
Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
